These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10928650)

  • 21. Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum.
    Björk T; Ljungberg B; Piironen T; Abrahamsson PA; Pettersson K; Cockett AT; Lilja H
    Urology; 1998 Jan; 51(1):57-62. PubMed ID: 9457289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does body mass index "dilute" the predictive property of prostate-specific antigen for tumor volume at radical prostatectomy?
    Mitchell CR; Umbreit EC; Rangel LJ; Bergstralh EJ; Karnes RJ
    Urology; 2011 Oct; 78(4):868-72. PubMed ID: 21843902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy.
    Schild SE; Buskirk SJ; Wong WW; Halyard MY; Swanson SK; Novicki DE; Ferrigni RG
    J Urol; 1996 Nov; 156(5):1725-9. PubMed ID: 8863580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy.
    Witherspoon LR; Lapeyrolerie T
    J Urol; 1997 Apr; 157(4):1322-8. PubMed ID: 9120931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
    Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
    J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.
    Rogers E; Ohori M; Kassabian VS; Wheeler TM; Scardino PT
    J Urol; 1995 Jan; 153(1):104-10. PubMed ID: 7526002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Is radical prostatectomy a suitable model for determination of PSA half-life?].
    Brändle E; Gottfried HW; Maier S; Flohr P; Steinbach G; Hautmann RE
    Urologe A; 1995 Sep; 34(5):419-23. PubMed ID: 7483161
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radical prostatectomy: survival outcome and correlation to prostate-specific antigen levels.
    Oberpenning F; Hamm M; Schmid HP; Hertle L; Semjonow A
    Anticancer Res; 2000; 20(6D):4969-72. PubMed ID: 11326649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ratio of free-to-total prostate specific antigen correlates with tumor volume in patients with increased prostate specific antigen.
    Grossklaus DJ; Shappell SB; Gautam S; Smith JA; Cookson MS
    J Urol; 2001 Feb; 165(2):455-8. PubMed ID: 11176395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.
    Partin AW; Piantadosi S; Subong EN; Kelly CA; Hortopan S; Chan DW; Wolfert RL; Rittenhouse HG; Carter HB
    Prostate Suppl; 1996; 7():35-9. PubMed ID: 8950362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
    Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
    Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
    Custovic Z; Kraus O; Tomaskovic I; Tarle M
    Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigative clinical study on prostate cancer part II: on the role of the pretreatment total PSA to free testosterone ratio as a marker assessing prostate cancer prognostic groups after radical retropubic prostatectomy.
    Porcaro AB; Monaco C; Romano M; Petrozziello A; Rubilotta E; Lacola V; Sava T; Ghimenton C; Caruso B; Antoniolli SZ; Migliorini F; Comunale L
    Urol Int; 2010; 85(2):152-8. PubMed ID: 20616526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources.
    Ravery V
    Semin Urol Oncol; 1999 Aug; 17(3):127-9. PubMed ID: 10462314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
    Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
    J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.